10-QPeriod: Q1 FY2007

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2007

Filed May 2, 2007For Securities:IDXX

Summary

IDEXX Laboratories Inc. reported strong first-quarter 2007 results, with total revenue increasing by 26% year-over-year to $211.2 million. This growth was driven by a robust performance across its key segments, particularly the Companion Animal Group (CAG), which saw a 24.4% revenue increase. The company also successfully executed several strategic acquisitions during the quarter, including the Critical Care Division of Osmetech plc and Vita-Tech Canada Inc., which are expected to contribute to future growth. Significant investments were made in property, plant, and equipment, and the company secured a new five-year revolving credit facility, enhancing its financial flexibility. Despite increased operating expenses, primarily due to acquisitions and R&D investments, the company's operating income saw a notable increase, demonstrating effective cost management and operational efficiency.

Key Highlights

  • 1Total revenue for Q1 2007 reached $211.2 million, a 26% increase compared to the same period last year.
  • 2Companion Animal Group (CAG) revenue grew by 24.4% to $173.4 million, driven by strong performance in instruments, consumables, and laboratory services.
  • 3The company completed several strategic acquisitions, including the Critical Care Division of Osmetech plc and Vita-Tech Canada Inc., expanding its market reach and product offerings.
  • 4Gross profit increased by 26% to $108.6 million, with the gross profit margin remaining stable at approximately 51%.
  • 5Operating income increased by 14.5% to $30.9 million, although operating expenses rose due to acquisitions and investments.
  • 6IDEXX entered into a new $125 million revolving credit facility maturing in March 2012, enhancing its liquidity and financial flexibility.
  • 7The company continues to invest in its future, with a capital expenditure plan of approximately $70 million for 2007, including headquarters expansion.

Frequently Asked Questions

Revenue growth was primarily driven by strong organic growth across its key segments, especially the Companion Animal Group, and incremental sales from recently acquired businesses. Favorable currency exchange rates also contributed to the revenue increase.

The company made significant acquisitions during the quarter, including Osmetech's Critical Care Division and Vita-Tech Canada Inc. These acquisitions contributed to revenue growth and expanded the company's market presence, particularly in the human point-of-care diagnostics and veterinary reference laboratory services sectors. These acquisitions also led to an increase in goodwill and intangible assets on the balance sheet.

IDEXX maintains a strong liquidity position, with ample cash, cash equivalents, and short-term investments. The company also secured a new, larger revolving credit facility, providing significant financial flexibility for ongoing operations, potential acquisitions, and share repurchases. Management believes its current resources are sufficient to fund its operational needs and strategic growth initiatives.

Key risks highlighted include potential challenges in maintaining growth rates, regulatory hurdles for product approvals, dependence on a limited number of suppliers, intense competition, fluctuations in distributor purchasing patterns, and risks associated with international operations. The company also noted its inexperience in the human point-of-care market following a recent acquisition.